Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Maria Gabriella Brasca(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Paolo Pevarello(Nerviano Medical Sciences), Walter Moretti(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Francesco Colotta(Humanitas University), Ciro Mercurio(Mylan (Switzerland)), Giovanni Cervi(Nerviano Medical Sciences), Valter Croci(Nerviano Medical Sciences), Francesca Quartieri(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Achille Panzeri(Nerviano Medical Sciences), Alexander D. Cameron(University of Warwick), Maristella Colombo(Nerviano Medical Sciences), Paola Vianello(Nerviano Medical Sciences), Roberto D’Alessio(Nerviano Medical Sciences), Elena Casale, Gabriella Traquandi(Nerviano Medical Sciences), Anna Vulpetti(Nerviano Medical Sciences), Fulvia Roletto(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Francesco Fiorentini(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences)
Cited by 128
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury
|Proceedings of the National Academy of Sciences|2004|339
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205